BChE/p38-α MAPK-IN-1

BChE/p38-α MAPK-IN-1 is a selective dual inhibitor targeting hBChE (IC50 = 772 nM) and p38α MAPK (IC50 = 191 nM) . It reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) in cells, improves scopolamine-induced cognitive impairment, alleviates LPS-induced spatial learning deficits, and exhibits anti-neuroinflammatory effects in mice, making it applicable for Alzheimer's disease (AD) research.